Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.

CONCLUSION: IMT significantly improved real-world health outcomes and cost the Chinese public health insurance payers less than one GDPPC to gain one QALY in Chinese MS-CD patients. PMID: 33244205 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/33244205?dopt=Abstract

Source: World Journal of Gastroenterology : WJG - November 7, 2020 Category: Gastroenterology Authors: Shi JH, Luo L, Chen XL, Pan YP, Zhang Z, Fang H, Chen Y, Chen WD, Cao Q Tags: World J Gastroenterol Source Type: research